RCTs supporting ACS guidelines lack representativeness of the diverse ACS population, highlighting a need for more inclusive trial designs.
Answers are grounded in this paper and cite their sources.
May limit ACS guideline applicability to underrepresented patients; leaves open the need for more inclusive trial designs.
Randomised clinical trials supporting CPGs for ACS are not fully representative of the diversity of the ACS population and their current standard of care. While some of these issues with representativeness may be explained by how evidence has been accrued over time, efforts should be made by trialists to ensure that the evidence supporting CPGs is representative of the wider ACS population.
No takes yet. Share an insight, caveat, or question.
Mas-Lladó et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: